Relationship between Fecal Calprotectin Level and Colonoscopy Findings in Ulcerative Colitis Patients Referred to the Gastroenterology Clinic, Gorgan, Iran (2020)
|
Maryam Esmailpour1 , Sima Besharat2 , Taghi Amiriani *3  |
1- Internal Assistant, Gastroenterology and Hepatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran. 2- Associate Professor, Ph.D in Biomedicine, Golestan Research Center of Gastroenterology & Hepatology (GRCGH), Golestan University of Medical Sciences, Gorgan, Iran; Clinical Research Development Unit (CRDU), Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran. 3- Associate Professor, Adult Gastroenterology and Liver Specialist, Gastroenterology and Hepatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran. , taghi.amiriani@gmail.com |
|
Abstract: (3780 Views) |
Background and Objective: The diagnosis of inflammatory bowel disease (IBD) is performed by colonoscopy, sampling, and histopathology. Stool calprotectin is a test showing the presence of inflammation in the gastrointestinal tract. This study was done to determine the relationship between the calprotectin level in the feces and endoscopic findings in ulcerative colitis patients referred to the gastroenterology clinic in Gorgan, Iran.
Methods: This descriptive-analytical study was performed on 100 patients with ulcerative colitis referred to the gastroenterology clinic of Sayad Shirazi Hospital, Gorgan, north of Iran during 2020. The patients were asked to collect their stool samples one day before the procedure (just after taking the drug for bowel cleansing). Bowel cleansing was done by administering polyethylene glycol solution dissolved in water. The activity of ulcerative colitis was measured using the disease activity score. According to this criterion, a score greater than or equal to 5 is considered an active disease. Patients were classified into two groups: extensive or pan-colitis and left-sided colitis. Stool samples were evaluated for calprotectin in a single laboratory using a commercially available kit (Calprest- EuorociationspA. Trieste) at normal values of less than 50mg/g. The relationship between stool calprotectin with colonoscopic findings was evaluated.
Results: The average duration of infection was 4±3.1 years in the time range of 1-14 years. The calprotectin level was less than 50 μg/g in 16 patients. Stool calprotectin less than 50 µg/g was seen in only 16 patients. There was no significant relationship between the level of calprotectin and the either age or gender of patients. Most patients (84%) had active disease based on colonoscopic findings. Left-sided involvement was seen in 60% of patients. Fecal calprotectin level was significantly higher in those with acute phase and those with severe disease (P<0.05). Additionally, the calprotectin level had no significant relationship with the location of bowel involvement, extension, and disease duration.
Conclusion: This study showed that the fecal calprotectin level in patients with ulcerative colitis had a significant relationship with the severity and activity of the disease in north of Iran. |
|
Keywords: Ulcerative Colitis [MeSH], Calprotectin [MeSH], Bowel Function [MeSH], Colonoscopy [MeSH] Article ID: Vol25-20 |
|
Full-Text [PDF 583 kb]
(9624 Downloads)
|
Type of Study: Original Articles |
Subject:
Internal Medicine
|
|
|
|
|
References |
1. Axelrad JE, Cadwell KH, Colombel JF, Shah SC. The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review. Therap Adv Gastroenterol. 2021 Mar; 14: 17562848211004493. doi: 10.1177/17562848211004493. [ DOI] [ PubMed] 2. Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018 Mar; 53(3): 305-53. doi: 10.1007/s00535-018-1439-1. [ DOI] [ PubMed] 3. Tavakoli P, Vollmer-Conna U, Hadzi-Pavlovic D, Grimm MC. A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration. Public Health Rev. 2021 May; 42: 1603990. doi: 10.3389/phrs.2021.1603990. [ DOI] [ PubMed] 4. Khaki-Khatibi F, Qujeq D, Kashifard M, Moein S, Maniati M, Vaghari-Tabari M. Calprotectin in inflammatory bowel disease. Clin Chim Acta. 2020 Nov; 510: 556-65. doi: 10.1016/j.cca.2020.08.025. [ DOI] [ PubMed] 5. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec; 68(Suppl 3): s1-s106. doi: 10.1136/gutjnl-2019-318484. [ DOI] [ PubMed] 6. Lężyk-Ciemniak E, Tworkiewicz M, Wilczyńska D, Szaflarska-Popławska A, Krogulska A. Usefulness of Testing for Fecal Calprotectin in Pediatric Gastroenterology Clinical Practice. Med Princ Pract. 2021; 30(4): 311-19. doi: 10.1159/000512631. [ DOI] [ PubMed] 7. Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut. 2021 Oct; 70(10): 1978-88. doi: 10.1136/gutjnl-2021-324855. [ DOI] [ PubMed] 8. Rokkas T, Portincasa P, Koutroubakis IE. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. J Gastrointestin Liver Dis. 2018 Sep; 27(3): 299-306. doi: 10.15403/jgld.2014.1121.273.pti. [ DOI] [ PubMed] 9. Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H, et al. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization. Int J Mol Med. 2018 Jan; 41(1): 107-18. doi: 10.3892/ijmm.2017.3244. [ DOI] [ PubMed] 10. Smith LA, Gaya DR. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol. 2012 Dec; 18(46): 6782-89. doi: 10.3748/wjg.v18.i46.6782. [ DOI] [ PubMed] 11. Lin JF, Chen JM, Zuo JH, Yu A, Xiao ZJ, Deng FH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014 Aug; 20(8): 1407-15. doi: 10.1097/MIB.0000000000000057. [ DOI] [ PubMed] 12. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015 Jun; 110(6): 802-19. doi: 10.1038/ajg.2015.120. [ DOI] [ PubMed] 13. Kawashima K, Ishihara S, Yuki T, Fukuba N, Oshima N, Kazumori H, et al. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol. 2016 Apr; 16: 47. doi: 10.1186/s12876-016-0462-z. [ DOI] [ PubMed] 14. Fu Y, Wang L, Xie C, Zou K, Tu L, Yan W, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep. 2017 Jun; 7(1): 2669. doi: 10.1038/s41598-017-02835-5. [ DOI] [ PubMed] 15. Mak WY, Buisson A, Andersen MJ Jr, Lei D, Pekow J, Cohen RD, et al. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5): 1294-301. doi: 10.1007/s10620-018-4980-0. [ DOI] [ PubMed] 16. Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, et al. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug; 13(8): 1012-24. doi: 10.1093/ecco-jcc/jjz023. [ DOI] [ PubMed] 17. Freeman K, Taylor-Phillips S, Willis BH, Ryan R, Clarke A. Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the IMRD-UK data. BMJ Open. 2021 Feb; 11(2): e044177. doi: 10.1136/bmjopen-2020-044177. [ DOI] [ PubMed]
|
|
Send email to the article author |
|
|
Esmailpour M, Besharat S, Amiriani T. Relationship between Fecal Calprotectin Level and Colonoscopy Findings in Ulcerative Colitis Patients Referred to the Gastroenterology Clinic, Gorgan, Iran (2020). J Gorgan Univ Med Sci 2023; 25 (2) :45-50 URL: http://goums.ac.ir/journal/article-1-4266-en.html
|